1
|
Li Y, Wang X, Chen S, Wu B, He Y, Du X, Yang X. Long non-coding RNA small nucleolar RNA host genes: functions and mechanisms in hepatocellular carcinoma. Mol Biol Rep 2022; 49:2455-2464. [PMID: 34989961 DOI: 10.1007/s11033-021-07018-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2021] [Accepted: 11/24/2021] [Indexed: 11/09/2022]
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system, with a high degree of malignancy. Although treatment methods are constantly improving, the mortality of patients is still very high, and the small nucleolar RNA host gene (SNHG) plays an important role in the occurrence and development of cancer. It can activate downstream signaling molecules by acting on microRNA and microRNA target genes, promote the proliferation, invasion, and migration of HCC cells, and provide a new molecular target for the treatment of HCC. At present, the molecular mechanisms of HCC remain unclear. In this study, the mechanism and signaling pathway of SNHG in HCC are reviewed, which provides a theoretical basis for the clinical treatment of HCC.
Collapse
Affiliation(s)
- Yuan Li
- College of Clinical Medicine, Ningxia Medical University, Yinchuan, 750000, China.,Department of General Surgery, Gansu Provincial Hospital, Lanzhou, 730000, China
| | - Xinxin Wang
- Department of General Surgery, Gansu Provincial Hospital, Lanzhou, 730000, China
| | - Shiyong Chen
- Department of General Surgery, Gansu Provincial Hospital, Lanzhou, 730000, China
| | - Biao Wu
- Department of General Surgery, Gansu Provincial Hospital, Lanzhou, 730000, China
| | - Yu He
- Department of General Surgery, Gansu Provincial Hospital, Lanzhou, 730000, China
| | - Xueqin Du
- Department of General Surgery, Gansu Provincial Hospital, Lanzhou, 730000, China
| | - Xiaojun Yang
- Department of General Surgery, Gansu Provincial Hospital, Lanzhou, 730000, China. .,School of People's Clinical Medicine, Lanzhou University, Lanzhou, 730000, China. .,Gansu Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology, Gansu Provincial Hospital, Lanzhou, 730000, China. .,Gansu Research Center of Prevention and Control Project for Digestive Oncology, Gansu Provincial Hospital, Lanzhou, 730000, China.
| |
Collapse
|
2
|
Zhang WT, Zhang GX, Gao SS. The Potential Diagnostic Accuracy of Circulating MicroRNAs for Leukemia: A Meta-Analysis. Technol Cancer Res Treat 2021; 20:15330338211011958. [PMID: 33902358 PMCID: PMC8085375 DOI: 10.1177/15330338211011958] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Background: Leukemia is a common malignant disease in the human blood system. Many researchers have proposed circulating microRNAs as biomarkers for the diagnosis of leukemia. We conducted a meta-analysis to evaluate the diagnostic accuracy of circulating miRNAs in the diagnosis of leukemia. Methods: A comprehensive literature search (updated to October 13, 2020) in PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang database and China National Knowledge Infrastructure (CNKI) was performed to identify eligible studies. The sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) for diagnosing leukemia were pooled for both overall and subgroup analysis. The meta-regression and subgroup analysis were performed to explore heterogeneity and Deeks’ funnel plot was used to assess publication bias. Results: 49 studies from 22 publications with a total of 3,489 leukemia patients and 2,756 healthy controls were included in this meta-analysis. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the curve were 0.83, 0.92, 10.8, 0.18, 59 and 0.94, respectively. Subgroup analysis shows that the microRNA clusters of plasma type could carry out a better diagnostic accuracy of leukemia patients. In addition, publication bias was not found. Conclusions: Circulating microRNAs can be used as a promising noninvasive biomarker in the early diagnosis of leukemia.
Collapse
Affiliation(s)
- Wen-Ting Zhang
- Xi'an Daxing Hospital, Shaanxi, China.,International Doctoral School, University of Seville, Spain
| | - Guo-Xun Zhang
- International Doctoral School, University of Seville, Spain
| | - Shuai-Shuai Gao
- Xi'an Daxing Hospital, Shaanxi, China.,International Doctoral School, University of Seville, Spain
| |
Collapse
|
3
|
Zhang YH, Bai SF, Yan JQ. Blood circulating miRNAs as biomarkers of Alzheimer's disease: a systematic review and meta-analysis. Biomark Med 2019; 13:1045-1054. [PMID: 31385521 DOI: 10.2217/bmm-2018-0341] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Aim: It is already known that miRNAs can be differentially expressed in Alzheimer's disease (AD). We aimed to evaluate the performance of miRNAs from blood as potential biomarkers for AD. Materials & methods: MEDLINE, PubMed and Embase were searched for studies about peripheral blood miRNAs that could discriminate patients with AD from cognitively normal controls. The data regarding the specificity and sensitivity were extracted. STATA 14.0 was used to analyze the data. Results: Ten studies containing 770 AD and 664 normal controls. The analysis showed that miRNAs presented excellent diagnostic performance and the overall sensitivity was 0.80 (95% CI: 0.75-0.83), specificity was 0.83 (95% CI: 0.78-0.87) and diagnostic odds ratio was 14 (95% CI: 11-19). Subgroup analysis suggested that the Caucasian group and blood group showed a better performance in AD diagnosis and the diagnostic odds ratio was 42 and 34, respectively. Conclusion: This meta-analysis showed that miRNAs may be a promising biomarkers for AD.
Collapse
Affiliation(s)
- Ya-Heng Zhang
- The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science & Technology, Luoyang 471003, PR China
| | - Shu-Feng Bai
- The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science & Technology, Luoyang 471003, PR China
| | - Jun-Qiang Yan
- The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science & Technology, Luoyang 471003, PR China
| |
Collapse
|
4
|
Drokow EK, Sun K, Ahmed HAW, Akpabla GS, Song J, Shi M. Circulating microRNA as diagnostic biomarkers for haematological cancers: a systematic review and meta-analysis. Cancer Manag Res 2019; 11:4313-4326. [PMID: 31190996 PMCID: PMC6520596 DOI: 10.2147/cmar.s199126] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2018] [Accepted: 03/10/2019] [Indexed: 12/31/2022] Open
Abstract
Purpose: Recent studies have validated microRNAs (miRNAs) as a diagnostic biomarker for haematological cancers. This study aimed to estimate the overall diagnostic accuracy of circulating miRNAs in haematological malignancies. Materials and Methods: Multiple databases (Google Scholar, PubMed, EMBASE, Cochrane Library,) were searched until 19th August 2017. Results: The meta-analysis included 50 studies from 20 publications. The diagnostic accuracy was assessed by pooled specificity, sensitivity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the curve area (AUC) by random effect model. We used QUADAS (Quality Assessment for diagnostic accuracy studies) to evaluate the quality of the included studies. To perform the meta-analysis, we used Meta-Disk 1.4, Revman 5.3 and Stata 12.0 software. High diagnostic accuracy was demonstrated, with a sensitivity of 0.81, a specificity of 0.85, a PLR of 5.28, an NLR of 0.22, a DOR of 30.39, and an AUC of 0.91. Subgroup analyses showed better outcomes for the African population, combined miRNAs and leukaemia patients compared with other subgroups. Conclusion: Our results indicated that circulating miRNAs especially combined miRNA can be used as a diagnostic marker in haematological cancers.
Collapse
Affiliation(s)
- Emmanuel Kwateng Drokow
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, Zhengzhou, People's Republic of China
| | - Kai Sun
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, Zhengzhou, People's Republic of China
| | - Hafiz Abdul Waqas Ahmed
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, Zhengzhou, People's Republic of China
| | - Gloria Selorm Akpabla
- Department of Pathophysiology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, People's Republic of China
| | - Juanjuan Song
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, Zhengzhou, People's Republic of China
| | - Mingyue Shi
- Department of Haematology, Zhengzhou University People's Hospital & Henan Provincial People's Hospital Henan, Zhengzhou, People's Republic of China
| |
Collapse
|
5
|
Zhou Q, Zuo MZ, He Z, Li HR, Li W. Identification of circulating microRNAs as diagnostic biomarkers for ovarian cancer:A pooled analysis of individual studies. Int J Biol Markers 2018; 33:1724600818766500. [PMID: 29683066 DOI: 10.1177/1724600818766500] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Circulating microRNAs (miRNAs) are proposed as promising non-invasive diagnostic biomarkers for many cancers. However, the diagnostic value of circulating miRNAs in ovarian cancer is inconsistent in different studies. Thus we performed this meta-analysis to systematically evaluate the diagnostic value of circulating miRNAs in ovarian cancer. METHODS Eligible studies that were published prior to 30 June 2017 were searched from the PubMed, EMBASE, Cochrane Library, and Chinese National Knowledge Infrastructure. All analyses were performed using STATA 12.0 software. A bivariate regression was used to calculate pooled diagnostic accuracy estimates. RESULTS A total of 36 studies from 16 publications were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of circulating miRNAs for ovarian cancer diagnosis were 0.76 (95% confidence intervals (CI): 0.69, 0.81), 0.81 (95% CI 0.74, 0.87), 4.00 (95% CI 2.70, 5.30), 0.30(95% CI 0.24, 0.37) and 13.00 (95% CI 9.00, 19.00), respectively. The area under the summary receiver operating characteristic curve was 0.85 (95% CI 0.82, 0.88). Subgroup analyses showed that multiple miRNA assays yielded better diagnostic characteristics than a single miRNA assay, and plasma miRNAs were better than serum miRNAs for ovarian cancer detection. CONCLUSION Circulating miRNAs, especially the combination of multiple circulating miRNAs, are promising biomarkers for the diagnosis of ovarian cancer. However, further large-scale prospective studies are necessary to validate the applicability of the miRNAs in the early detection of ovarian cancer.
Collapse
Affiliation(s)
- Quan Zhou
- Department of Gynecology and Obstetrics, the People's Hospital of Three Gorges University/The First People's Hospital of Yichang, Yichang, China
| | - Man-Zhen Zuo
- Department of Gynecology and Obstetrics, the People's Hospital of Three Gorges University/The First People's Hospital of Yichang, Yichang, China
| | - Ze He
- Department of Gynecology and Obstetrics, the People's Hospital of Three Gorges University/The First People's Hospital of Yichang, Yichang, China
| | - Hai-Rong Li
- Department of Gynecology and Obstetrics, the People's Hospital of Three Gorges University/The First People's Hospital of Yichang, Yichang, China
| | - Wei Li
- Department of Gynecology and Obstetrics, the People's Hospital of Three Gorges University/The First People's Hospital of Yichang, Yichang, China
| |
Collapse
|
6
|
Swellam M, Hashim M, Mahmoud MS, Ramadan A, Hassan NM. Aberrant Expression of Some Circulating miRNAs in Childhood Acute Lymphoblastic Leukemia. Biochem Genet 2018; 56:283-294. [PMID: 29460192 DOI: 10.1007/s10528-018-9844-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Accepted: 01/27/2018] [Indexed: 01/23/2023]
Abstract
Acute lymphoblastic leukemia (ALL) is a heterogeneous cancer commonly affecting children due to dysregulation of miRNA expression. In the current study, authors investigated the expression profile for miRNA-125b-1 and miRNA-203 among childhood ALL. Blood samples were collected from newly diagnosed childhood ALL and healthy control children. The expression profile for candidate miRNAs was detected using quantitative RT-PCR analysis. Statistical analysis were performed using receiver operating characteristic curve (ROC) to examine the diagnostic efficacy of the two miRNA and their levels among ALL clinicopathological factors and phenotypes. The median expression level for miRNA-125b-1 was significantly high in childhood ALL; while miRNA-203 level was significantly low in childhood ALL as compared to control ones. MiRNA-125-1 reported significant increase in T-ALL as compared to other ALL phenotypes. Median miRNA-203 level was high in T-ALL followed by pre-B-ALL although no significant difference was reported. Clinicopathological factors did not emphasize significance with either detected miRNAs. Using ROC curve the diagnostic efficacy was significant with an area under the curve 0.858 for miRNA-125b-1 (83.72, 100%) and 0.878 for miRNA-203 (97.67, 86.96%). The combination of the two key miRNAs revealed absolute sensitivity (100%). MiRNA-125b-1 and miRNA-203 can be useful molecular markers for diagnosis of ALL. Further studies with large cohort are warranted to validate these results.
Collapse
Affiliation(s)
- Menha Swellam
- Genetic Engineering and Biotechnology Research Division, Biochemistry Department, High Throughput Molecular and Genetic laboratory, Center for Excellences for Advanced Sciences, National Research Centre, El-Bohouth Street, Dokki, Giza, 12622, Egypt. .,Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Giza, Egypt.
| | - Maha Hashim
- Genetic Engineering and Biotechnology Research Division, Biochemistry Department, High Throughput Molecular and Genetic laboratory, Center for Excellences for Advanced Sciences, National Research Centre, El-Bohouth Street, Dokki, Giza, 12622, Egypt.,Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Giza, Egypt
| | - Magda Sayed Mahmoud
- Genetic Engineering and Biotechnology Research Division, Biochemistry Department, High Throughput Molecular and Genetic laboratory, Center for Excellences for Advanced Sciences, National Research Centre, El-Bohouth Street, Dokki, Giza, 12622, Egypt.,Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Giza, Egypt
| | - Amal Ramadan
- Genetic Engineering and Biotechnology Research Division, Biochemistry Department, High Throughput Molecular and Genetic laboratory, Center for Excellences for Advanced Sciences, National Research Centre, El-Bohouth Street, Dokki, Giza, 12622, Egypt.,Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Giza, Egypt
| | - Naglaa M Hassan
- Department of Clinical Pathology, National Cancer Institute, Cairo, Egypt
| |
Collapse
|
7
|
Shi HB, Yu JX, Yu JX, Feng Z, Zhang C, Li GY, Zhao RN, Yang XB. Diagnostic significance of microRNAs as novel biomarkers for bladder cancer: a meta-analysis of ten articles. World J Surg Oncol 2017; 15:147. [PMID: 28774300 PMCID: PMC5543742 DOI: 10.1186/s12957-017-1201-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2016] [Accepted: 07/08/2017] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Previous studies have revealed the importance of microRNAs' (miRNAs) function as biomarkers in diagnosing human bladder cancer (BC). However, the results are discordant. Consequently, the possibility of miRNAs to be BC biomarkers was summarized in this meta-analysis. METHODS In this study, the relevant articles were systematically searched from CBM, PubMed, EMBASE, and Chinese National Knowledge Infrastructure (CNKI). The bivariate model was used to calculate the pooled diagnostic parameters and summary receiver operator characteristic (SROC) curve in this meta-analysis, thereby estimating the whole predictive performance. STATA software was used during the whole analysis. RESULTS Thirty-one studies from 10 articles, including 1556 cases and 1347 controls, were explored in this meta-analysis. In short, the pooled sensitivity, area under the SROC curve, specificity, positive likelihood ratio, diagnostic odds ratio, and negative likelihood ratio were 0.72 (95%CI 0.66-0.76), 0.80 (0.77-0.84), 0.76 (0.71-0.81), 3.0 (2.4-3.8), 8 (5.0-12.0), and 0.37 (0.30-0.46) respectively. Additionally, sub-group and meta-regression analyses revealed that there were significant differences between ethnicity, miRNA profiling, and specimen sub-groups. These results suggested that Asian population-based studies, multiple-miRNA profiling, and blood-based assays might yield a higher diagnostic accuracy than their counterparts. CONCLUSIONS This meta-analysis demonstrated that miRNAs, particularly multiple miRNAs in the blood, might be novel, useful biomarkers with relatively high sensitivity and specificity and can be used for the diagnosis of BC. However, further prospective studies with more samples should be performed for further validation.
Collapse
Affiliation(s)
- Hong-Bin Shi
- Department of Urology, Ningxia People's Hospital, No. 301 North Zhengyuan Street, Jinfeng District, Yinchuan, 750021, Ningxia, China
| | - Jia-Xing Yu
- Ningxia Medical University, Yinchuan, 750004, Ningxia, China
| | - Jian-Xiu Yu
- Ningxia Medical University, Yinchuan, 750004, Ningxia, China
| | - Zheng Feng
- Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China
| | - Chao Zhang
- Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China
| | - Guang-Yong Li
- Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China
| | - Rui-Ning Zhao
- Department of Urology, General Hospital of Ningxia Medical University, Yinchuan, 750004, Ningxia, China
| | - Xiao-Bo Yang
- Department of Urology, Ningxia People's Hospital, No. 301 North Zhengyuan Street, Jinfeng District, Yinchuan, 750021, Ningxia, China.
| |
Collapse
|
8
|
Elhamamsy AR, El Sharkawy MS, Zanaty AF, Mahrous MA, Mohamed AE, Abushaaban EA. Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia. INTERNATIONAL JOURNAL OF MOLECULAR AND CELLULAR MEDICINE 2017; 6:77-86. [PMID: 28890884 PMCID: PMC5581549 DOI: 10.22088/acadpub.bums.6.2.2] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/30/2016] [Accepted: 02/27/2017] [Indexed: 02/05/2023]
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that function as post-transcriptional gene expression regulators. The expression profiling of miRNAs has already entered into cancer clinics as diagnostic and prognostic biomarkers to assess tumor initiation, progression and response to treatment in cancer patients. Recent studies have opened the way for the use of circulating miRNAs as non-invasive diagnosis and prognosis of Acute myeloid leukemia (AML). The aim of this study was to identify plasma miR-92a, miR-143 and miR-342 expression signatures in AML patients to introduce new markers for establishing AML diagnosis and prognosis. Blood samples were collected from 65 AML patients and 50 controls. The expression of three target miRNAs (miR-92a, miR-143 and miR-342) was measured using quantitative real-time PCR method. Plasma levels of miR-92a, miR-143 and miR-342 were significantly lower in AML patients in comparison with control group. Receiver operator characteristic (ROC) analysis revealed that the sensitivity and specificity values of miR-92a were 81.5% and 94%, respectively, with a cut-off value of 0.704. The sensitivity and specificity values of miR-143 were 87.7% and 80%, respectively, with a cut-off value of 0.65. The sensitivity and specificity values of miR-342 were 75.4% and 90%, respectively, with a cut-off value of 0.479. Our findings suggest that plasma miR-92a, miR-143 and miR-342 could be promising novel circulating biomarkers in clinical detection of AML.
Collapse
Affiliation(s)
- Amr Rafat Elhamamsy
- Department of Clinical Pharmacy, School of Pharmacy, Tanta University, 31516 Tanta, Egypt.,Department of Clinical Pharmacy, Tanta Cancer Center, 31527 Tanta, Egypt
| | | | | | - Mohammed Ahmed Mahrous
- Department of Clinical Pharmacy, School of Pharmacy, Tanta University, 31516 Tanta, Egypt.,Department of Clinical Pharmacy, Tanta Cancer Center, 31527 Tanta, Egypt
| | | | | |
Collapse
|
9
|
Labib HA, Elantouny NG, Ibrahim NF, Alnagar AA. Upregulation of microRNA-21 is a poor prognostic marker in patients with childhood B cell acute lymphoblastic leukemia. Hematology 2017; 22:392-397. [DOI: 10.1080/10245332.2017.1292204] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Affiliation(s)
| | - Neveen G. Elantouny
- Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| | - Nevin F. Ibrahim
- Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| | - Ahmed A. Alnagar
- Medical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
| |
Collapse
|
10
|
Zhang H, Zhou D, Ying M, Chen M, Chen P, Chen Z, Zhang F. Expression of Long Non-Coding RNA (lncRNA) Small Nucleolar RNA Host Gene 1 (SNHG1) Exacerbates Hepatocellular Carcinoma Through Suppressing miR-195. Med Sci Monit 2016; 22:4820-4829. [PMID: 27932778 PMCID: PMC5167104 DOI: 10.12659/msm.898574] [Citation(s) in RCA: 94] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Background Aberrant expression of lncRNA has been suggested to have an association with tumorigenesis. Our study was designed to reveal the underlying connection between lncRNA SNHG1 and hepatocellular carcinoma (HCC) pathogenesis. Material/Methods A total of 122 pairs of HCC tissues (case group) and matched adjacent non-tumor liver tissues (control group) were collected for this study. RT-PCR and in situ hybridization were conducted to investigate differences in lncRNA SNHG1 expression between the case and control group. The expression levels of lncRNA SNHG1 and miR-195 in HepG2 cells transfected with SNHG1-mimic and SNHG1-inhibitor were measured by RT-PCR. The proliferation, invasion, and migration status of HepG2 cells after transfection were assessed through MTT assay, wound healing assay, and Transwell assay, respectively. Whether miR-195 is a direct downstream target of lncRNA SNHG1 was verified by both bioinformatics target gene prediction and dual-luciferase report assay. Results The expression level of lncRNA SNHG1 was remarkably upregulated in HCC tissues and cell lines compared with normal tissues and cell lines. High expression of lncRNA SNHG1 contributed to the downregulation of miR-195 in HepG2 cells. Also, lncRNA SNHG1 exacerbated HCC cell proliferation, invasion, and migration in vitro through the inhibition of miR-195. This suggests that miR-195 is a direct downstream target of lncRNA SNHG1. Conclusions lncRNA SNHG1 may contribute to the aggravation of HCC through the inhibition of miR-195.
Collapse
Affiliation(s)
- Hui Zhang
- Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, Fujian, China (mainland)
| | - Dong Zhou
- Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, Fujian, China (mainland)
| | - Mingang Ying
- Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, Fujian, China (mainland)
| | - Minyong Chen
- Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, Fujian, China (mainland)
| | - Peng Chen
- Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, Fujian, China (mainland)
| | - Zhaoshuo Chen
- Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, Fujian, China (mainland)
| | - Fan Zhang
- Department of Abdominal Surgery, Fujian Provincial Cancer Hospital, Fujian Medical University Teaching Hospital, Fuzhou, Fujian, China (mainland)
| |
Collapse
|
11
|
Zhang L, Cao D, Tang L, Sun C, HU Y. A panel of circulating mi
RNA
s as diagnostic biomarkers for screening multiple myeloma: a systematic review and meta‐analysis. Int J Lab Hematol 2016; 38:589-599. [PMID: 27870469 DOI: 10.1111/ijlh.12560] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2016] [Accepted: 07/05/2016] [Indexed: 12/13/2022]
Affiliation(s)
- L. Zhang
- Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
| | - D. Cao
- Institute of Cancer Renmin Hospital of Wuhan University Wuhan University WuhanChina
| | - L. Tang
- Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
- Collaborative Innovation Center of Hematology Huazhong University of Science and Technology Wuhan Hubei China
| | - C. Sun
- Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
- Collaborative Innovation Center of Hematology Huazhong University of Science and Technology Wuhan Hubei China
| | - Y. HU
- Department of Hematology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan China
- Collaborative Innovation Center of Hematology Huazhong University of Science and Technology Wuhan Hubei China
| |
Collapse
|
12
|
Swellam M, El-Khazragy N. Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia. Tumour Biol 2016; 37:10571-6. [PMID: 26857279 DOI: 10.1007/s13277-016-4948-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Accepted: 01/29/2016] [Indexed: 01/03/2023] Open
Abstract
Aberrant microRNA (miRNA) expression participates in childhood acute lymphoblastic leukemia (ALL). This study aimed to investigate the expression of miRNA-100, miRNA-196a, and miRNA-146a among childhood ALL and study their correlation with other hematological parameters and different phenotypes. Peripheral blood mononuclear cells (PMNCs) were obtained from 85 childhood ALL and 25 healthy children for the detection of miRNA expression using quantitative real-time PCR. Significant higher median levels were reported for ALL compared to control children. The diagnostic efficacy for miRNA-146a was superior as both sensitivity and specificity were absolute. A significant correlation was observed between higher expression of miRNA-100 and lower platelet and lymphocyte counts; high expression of miRNA-146a showed significant correlation with low total leukocyte count (TLC) and lymphocyte counts. Significant relation was reported between studied miRNAs and different phenotyping. miRNA-100, miRNA-196a, and miRNA-146a have significant role in childhood ALL leukemogenesis, and they may be useful as biological diagnostic molecular markers.
Collapse
Affiliation(s)
- Menha Swellam
- Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Centre, Giza, 12622, Dokki, Egypt.
| | - Nashwa El-Khazragy
- Department of Clinical Pathology, Oncology Diagnostic Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt
| |
Collapse
|
13
|
Wang YX, Zhang TJ, Yang DQ, Yao DM, Yang L, Zhou JD, Deng ZQ, Ma JC, Guo H, Wen XM, Lin J, Qian J. Reduced miR-215 expression predicts poor prognosis in patients with acute myeloid leukemia. Jpn J Clin Oncol 2016; 46:350-6. [PMID: 26802165 DOI: 10.1093/jjco/hyv204] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2015] [Accepted: 12/16/2015] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE Abnormal expression of microRNA-215 has been identified in a variety of solid cancers. However, little is known about the expression pattern of microRNA-215 in acute myeloid leukemia. This study was to investigate the status of microRNA-215 expression and further analyze its clinical significance in acute myeloid leukemia. METHODS Real-time quantitative polymerase chain reaction assay was performed to evaluate the expression level of microRNA-215 in 113 patients with acute myeloid leukemia. Besides, the relationship between microRNA-215 levels and clinical and pathological factors was explored. RESULTS Compared with the healthy individuals, microRNA-215 expression in acute myeloid leukemia patients was significantly down-regulated (P= 0.001). MicroRNA-215 low-expressed patients had higher white blood cells than microRNA-215 high-expressed patients (P= 0.014). The incidence of FLT3/ITD mutation in the patients with low microRNA-215 expression was significantly higher than those with high microRNA-215 expression (P= 0.025). MicroRNA-215 low-expressed patients had significantly shorter overall survival than microRNA-215 high-expressed patients in both non-M3 acute myeloid leukemia patients and cytogenetically normal patients (P= 0.017 and P= 0.044, respectively). Meanwhile, multivariate analysis confirmed the adverse prognostic value of microRNA-215 expression in acute myeloid leukemia patients with non-M3 subtypes. CONCLUSIONS Our study demonstrates that reduced microRNA-215 expression is a common event and is associated with poor clinical outcome in acute myeloid leukemia.
Collapse
Affiliation(s)
- Yu-Xin Wang
- Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu
| | - Ting-Juan Zhang
- Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu
| | - Dong-Qin Yang
- Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu
| | - Dong-Ming Yao
- Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China
| | - Lei Yang
- Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu
| | - Jing-Dong Zhou
- Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu
| | - Zhao-Qun Deng
- Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China
| | - Ji-Chun Ma
- Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China
| | - Hong Guo
- Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China
| | - Xiang-Mei Wen
- Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China
| | - Jiang Lin
- Laboratory Center, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China
| | - Jun Qian
- Department of Hematology, Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu
| |
Collapse
|
14
|
Wang F, Jiang C, Sun Q, Yan F, Wang L, Fu Z, Liu T, Hu F. miR-195 is a key regulator of Raf1 in thyroid cancer. Onco Targets Ther 2015; 8:3021-8. [PMID: 26527888 PMCID: PMC4621222 DOI: 10.2147/ott.s90710] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Proto-oncogene Raf1 serves as a part of the mitogen-activated protein kinases/extracellular signal-regulated kinase signal transduction pathway and regulates cell migration, apoptosis, and differentiation. Although a large number of studies have shown that Raf1 is overexpressed in various kinds of cancer, little is known about the association between Raf1 and miRNAs in thyroid carcinoma. This study proves that Raf1 is overexpressed in thyroid cancer, which has been confirmed by many other studies. Besides, we identify that Raf1 is a direct target of miR-15a/b, miR-16, and miR-195 by dual luciferase reporter assay. We also find that the expression of miR-195 is downregulated in 50 pairs of thyroid tumor tissues compared to the adjacent nontumor tissues, while there is no difference in the expression of miR-15a/b and miR-16 between the groups. Furthermore, exogenous overexpression of miR-195 significantly inhibits the protein expression of Raf1 and blocks the thyroid cancer cell proliferation. Our findings delineate a novel mechanism for the regulation of Raf1 in thyroid cancer, which may help to provide a new direction for the treatment of thyroid cancer.
Collapse
Affiliation(s)
- Fangzheng Wang
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China ; Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China
| | - Chuner Jiang
- Department of Breast Surgery, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China
| | - Quanquan Sun
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China ; Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China
| | - Fenqin Yan
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China ; Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China
| | - Lei Wang
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China ; Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China
| | - Zhenfu Fu
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China ; Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China
| | - Tongxin Liu
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China ; Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China
| | - Fujun Hu
- Department of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China ; Zhejiang Key Laboratory of Radiation Oncology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, People's Republic of China
| |
Collapse
|
15
|
Luan C, Yang Z, Chen B. The functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapy. Onco Targets Ther 2015; 8:2903-14. [PMID: 26508875 PMCID: PMC4610789 DOI: 10.2147/ott.s92470] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
MicroRNAs (miRNAs), a new class of noncoding RNAs, which can hybridize to target messenger RNAs and regulate their expression posttranscriptionally, express differentially in distinct stages of lymphopoiesis and influence the direction of lymphoid precursor maturation. Hence, there is aberrant expression of miRNAs involved in malignant lymphopoiesis, and these aberrations can be used as signatures of acute lymphoblastic leukemia (ALL) with different subtypes. In addition, changes in the expression of several miRNAs may have functional relevance with leukemogenesis or drug resistance. As a result, the reversal of the expression of these miRNAs may alleviate the disease to some extent and improve clinical outcomes. However, among the studies of miRNAs, there are still some problems that need to be solved to understand the function of miRNAs in ALL more thoroughly.
Collapse
Affiliation(s)
- Chengxin Luan
- Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China
| | - Zixue Yang
- State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing, People's Republic of China
| | - Baoan Chen
- Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China
| |
Collapse
|
16
|
MicroRNA-155 hallmarks promising accuracy for the diagnosis of various carcinomas: results from a meta-analysis. DISEASE MARKERS 2015; 2015:327287. [PMID: 25918453 PMCID: PMC4397007 DOI: 10.1155/2015/327287] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/24/2014] [Accepted: 02/27/2015] [Indexed: 01/06/2023]
Abstract
Background. Recent studies have shown that microRNAs (miRNAs) have diagnostic values in various cancers. This meta-analysis seeks to summarize the global diagnostic role of miR-155 in patients with a variety of carcinomas. Methods. Eligible studies were retrieved by searching the online databases, and the bivariate meta-analysis model was employed to generate the summary receiver operator characteristic (SROC) curve. Results. A total of 17 studies dealing with various carcinomas were finally included. The results showed that single miR-155 testing allowed for the discrimination between cancer patients and healthy donors with a sensitivity of 0.82 (95% CI: 0.73–0.88) and specificity of 0.77 (95% CI: 0.70–0.83), corresponding to an area under curve (AUC) of 0.85, while a panel comprising expressions of miR-155 yielded a sensitivity of 0.76 (95% CI: 0.68–0.82) and specificity of 0.82 (95% CI: 0.77–0.86) in diagnosing cancers. The subgroup analysis displayed that serum miR-155 test harvested higher accuracy than plasma-based assay (the AUC, sensitivity, and specificity were, resp., 0.87 versus 0.73, 0.78 versus 0.74, and 0.77 versus 0.70). Conclusions. Our data suggest that single miR-155 profiling has a potential to be used as a screening test for various carcinomas, and parallel testing of miR-155 confers an improved specificity compared to single miR-155 analysis.
Collapse
|
17
|
Abstract
DNA methylation and histone modification are epigenetic mechanisms that result in altered gene expression and cellular phenotype. The exact role of methylation in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) remains unclear. However, aberrations (e.g. loss-/gain-of-function or up-/down-regulation) in components of epigenetic transcriptional regulation in general, and of the methylation machinery in particular, have been implicated in the pathogenesis of these diseases. In addition, many of these components have been identified as therapeutic targets for patients with MDS/AML, and are also being assessed as potential biomarkers of response or resistance to hypomethylating agents (HMAs). The HMAs 5-azacitidine (AZA) and 2'-deoxy-5-azacitidine (decitabine, DAC) inhibit DNA methylation and have shown significant clinical benefits in patients with myeloid malignancies. Despite being viewed as mechanistically similar drugs, AZA and DAC have differing mechanisms of action. DAC is incorporated 100% into DNA, whereas AZA is incorporated into RNA (80-90%) as well as DNA (10-20%). As such, both drugs inhibit DNA methyltransferases (DNMTs; dependently or independently of DNA replication) resulting in the re-expression of tumor-suppressor genes; however, AZA also has an impact on mRNA and protein metabolism via its inhibition of ribonucleotide reductase, resulting in apoptosis. Herein, we first give an overview of transcriptional regulation, including DNA methylation, post-translational histone-tail modifications, the role of micro-RNA and long-range epigenetic gene silencing. We place special emphasis on epigenetic transcriptional regulation and discuss the implication of various components in the pathogenesis of MDS/AML, their potential as therapeutic targets, and their therapeutic modulation by HMAs and other substances (if known). The main focus of this review is laid on dissecting the rapidly evolving knowledge of AZA and DAC with a special focus on their differing mechanisms of action, and the effect of HMAs on transcriptional regulation.
Collapse
Affiliation(s)
- Lisa Pleyer
- 3rd Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Laboratory for Immunological and Molecular Cancer Research, Oncologic Center, Paracelsus Medical University Hospital Salzburg, Center for Clinical Cancer and Immunology Trials at Salzburg Cancer Research Institute , Salzburg , Austria
| | | |
Collapse
|
18
|
Stankova M, Kubaczkova V, Sedlarikova L, Sevcikova S. Circulating microRNA as Biomarkers in Hematological Malignancies. EXPERIENTIA SUPPLEMENTUM (2012) 2015; 106:123-138. [PMID: 26608201 DOI: 10.1007/978-3-0348-0955-9_5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Hematopoiesis is a highly regulated process controlled by a complex network of molecular mechanisms that simultaneously regulate differentiation, proliferation, and apoptosis of hematopoietic stem cells. Aberrant microRNA (miRNA) expression could affect normal hematopoiesis, leading to the development of hematological malignancies. Hematologic cancers, which are caused by malignant transformation of cells of the bone marrow and the lymphatic system, are usually divided into three major groups: leukemias, lymphomas, and monoclonal gammopathies. Hematologic malignancies are highly aggressive diseases with high morbidity and mortality. For these reasons, early and easily obtainable markers for diagnosis, risk stratification, and follow-up are essential for improvement of outcome and survival of these patients. Recent studies have provided new insights about the diagnostic value of expression patterns of miRNAs in serum/plasma in these diseases. While the use of circulating miRNAs is only at the experimental level, it appears to have a great potential. This chapter deals with the use of circulating miRNAs as minimally invasive biomarkers in hematologic malignancies.
Collapse
Affiliation(s)
- Monika Stankova
- Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic
| | - Veronika Kubaczkova
- Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic
| | - Lenka Sedlarikova
- Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic
| | - Sabina Sevcikova
- Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Kamenice 5, Brno, 625 00, Czech Republic.
| |
Collapse
|
19
|
Circulating MicroRNA as Potential Source for Neurodegenerative Diseases Biomarkers. Mol Neurobiol 2014; 52:1494-1503. [PMID: 25367880 DOI: 10.1007/s12035-014-8944-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2014] [Accepted: 10/16/2014] [Indexed: 01/03/2023]
Abstract
An increasing number of circulating micro-ribonucleic acids (microRNAs, miRNAs) have been discovered its potential as biomarkers to diagnose neurodegenerative diseases (NDs) by many researchers. However, there were obvious inconsistencies among previous studies, and thus we performed this meta-analysis to evaluate whether miRNA is an effective biomarker with high accuracy to diagnose the NDs. PubMed, MEDLINE, EMBASE, the Cochrane Library, and other related databases were used to search eligible articles. The data of sensitivity and specificity were employed to plot the summary receiver operator characteristic (SROC) curve and calculate the area under the SROC curve (AUC). I (2) test were used to estimate the heterogeneity among different studies. In addition, the possible sources of heterogeneity were further explored by subgroup analyses and meta-regression. All analyses were performed by STATA 12.0 software. In this meta-analysis, eight publications with 459 NDs patients and 340 healthy controls were included to investigate the diagnostic performance of circulating miRNAs for NDs. The overall sensitivity and specificity, positive likelihood ratio (PLR), negative likelihood ration (NLR), and diagnostic odds ratio (DOR) were 0.83 (95% confidence interval (CI) 0.77-0.88), 0.87 (95% CI 0.83-0.89), 6.2 (95% CI 4.9-7.9), 0.19 (95% CI 0.14-0.27), 33 (95% CI 20-52), and 0.91 (95% CI: 0.88-0.93), respectively. The overall SROC curve was plotted with AUC of 0.91 (95% CI 0.88-0.93), which indicated an excellent diagnostic performance of circulating miRNA for NDs. Subgroup analysis based on miRNA profile demonstrated that multiple-miRNA assay had higher diagnostic accuracy for NDs when compared with single-miRNA assay. In conclusion, the circulating miRNAs may be the potential biomarkers in the clinical diagnosis of NDs, and the diagnostic accuracy would be better by using multiple-miRNA assay. However, large-scale studies are still needed to explore the relation between the circulating miRNA dysregulation and the pathological mechanism of NDs.
Collapse
|
20
|
Cui Z, Lin D, Song W, Chen M, Li D. Diagnostic value of circulating microRNAs as biomarkers for breast cancer: a meta-analysis study. Tumour Biol 2014; 36:829-39. [PMID: 25296735 DOI: 10.1007/s13277-014-2700-8] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Accepted: 10/01/2014] [Indexed: 01/14/2023] Open
Abstract
Recent studies have provided new insights into the diagnostic value of circulating microRNAs (miRNAs) for breast cancer (BCa). However, the inconsistent results between studies have prevented the widespread usage of miRNAs in clinics. To systematically assess the potential diagnostic value of circulating miRNAs in BCa, we performed a comprehensive meta-analysis. Eligible studies were retrieved by searching electronic databases. The quality of the studies was assessed on the basis of quality assessment for studies of diagnostic accuracy (QUADAS) criteria. The bivariate meta-analysis model was employed to summarize the diagnostic indices and plot the summary receiver operator characteristic (SROC) curve. A total of 15 studies were included in this meta-analysis, involving 1368 BCa patients and 849 healthy controls. Our bivariate random effects meta-analysis yielded an area under curve (AUC) value of 0.9217, with a sensitivity of 0.82 (95 % confidence interval (CI) 0.80-0.83) and specificity of 0.82 (95% CI 0.80-0.85) for the use of miRNAs in differentiating BCa patients from healthy controls. Notably, our subgroup analysis suggested that a combination of multiple miRNAs (AUC, sensitivity, and specificity of 0.9518, 0.87, and 0.88, respectively) seemed to harbor higher accuracy than single miRNA-based assays (AUC, sensitivity, and specificity of 0.8923, 0.79, and 0.77, respectively). Altogether, our data indicate that circulating miRNA profiling has a potential to be used as a screening test for BCa, among which, the detection of a combined multiple miRNAs may be a more comprehensive indicator than individual miRNA.
Collapse
Affiliation(s)
- Zhaolei Cui
- Department of Clinical Laboratory, School of Medical Technology and Engineering, Fujian Medical University, 88 Jiaotong Road, Taijiang, Fuzhou, 350004, Fujian, China
| | | | | | | | | |
Collapse
|